| Literature DB >> 35170374 |
Yan-Yu Peng1, Dan Sun1, Yan Xin1.
Abstract
Gastric cancer (GC) is one of the most common cancers in the world. Circular RNAs (circRNAs) are a class of non-coding RNAs that are widely expressed in eukaryotic cells. However, their role has been poorly understood in GC. This report aimed to explore the biological functions of hsa_circ_0005230 and its action mechanism in GC. This study validated that hsa_circ_0005230 was significantly up-regulated in 130 cases of GC tissues using qRT-PCR, and clinicopathological feature analysis revealed that its high expression was positively associated with histological grade, lymph node metastasis, TNM stages, and poor prognosis. In vitro, functional experiments showed that silencing hsa_circ_0005230 significantly decreased GC cell proliferation, invasion and migration capabilities. In addition, the major proteins of EMT (epithelial-mesenchymal transition) relevance have changed. In mechanism studies, bioinformatics analyses were used to predict the hsa_circ_0005230/miR-1299/RHOT1 axis and hsa_circ_0005230 may serve as a sponge for miR-1299 and indirectly regulate the expression of RHOT1. The regulated relationships between the molecules on the axis were verified using qRT-PCR and correlation analysis. Dual-luciferase reporter gene assay has been used to verify the binding site between miR-1299 and RHOT1. WB (Western blotting) and IHC (Immunohistochemical) were used to verify that RHOT1 may play the role of oncoprotein and affect the biological behavior of GC. Overall, hsa_circ_0005230 could enhance the EMT phenotype by promoting RHOT1 expression through sponging miR-1299, thus affecting the biological behavior of GC. Hsa_circ_0005230 can be easily identified as a potential diagnostic biomarker and assessment prognosis target for GC.Entities:
Keywords: Hsa_circ_0005230; RHOT1; gastric cancer; invasion; miR-1299; migration
Mesh:
Substances:
Year: 2022 PMID: 35170374 PMCID: PMC8973856 DOI: 10.1080/21655979.2022.2036514
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Specific primers for qRT-PCR
| Primer name | Primer sequence (5′-3′) | Length (bp) |
|---|---|---|
| hsa_circ_0005230 | F: 5’-CTCTTTGTTTTGCACACTAGGGA-3’ | 23 |
| R: 5’-ACCAGGTGAGCAGTCAAGAA-3’ | 20 | |
| miR-1299 | F: 5’-TTCTGGAATTCTGTGTGAGGGA-3’ | 22 |
| U6 | F: 5’-TTCTGGAATTCTGTGTGAGGGA-3’ | 22 |
| R: 5’-GGAACGATACAGACAACATTAGC-3’ | 23 | |
| RHOT1 | F: 5’-CTGATTTCTGCAGGAAACACAA-3’ | 22 |
| R: 5’-GCAAAAACAGTAGCACCAAAAC-3’ | 22 | |
| GAPDH | F: 5’-GAGTCAACGGATTTGGTCGT-3’ | 20 |
| R: 5’- TTGATTTTGGAGGGATCTCG-3’ | 20 |
Figure 1.The biological structure of hsa_circ_0005230 and its expression in GC tissues and cells.
Relationship between different hsa_circ_0005230 expression and clinicopathological features of GC
| Clinic characteristics | Total | hsa_circ_0005230 | χ2 | ||
|---|---|---|---|---|---|
| High(%) | Low | ||||
| Gender | 2.148 | 0.143 | |||
| Male | 93 | 63 (67.7) | 30 | ||
| Female | 37 | 20 (54.1) | 17 | ||
| Age(year) | 0.129 | 0.72 | |||
| ≤60 | 39 | 24 (61.5) | 15 | ||
| >60 | 91 | 59 (64.8) | 32 | ||
| Location | 0.104 | ||||
| Gastroesophageal | 8 | 6 (75) | 2 | ||
| Fundus/Cardia | 5 | 5 (100) | 0 | ||
| body | 34 | 19 (55.9) | 15 | ||
| Antrum | 81 | 51 (63) | 30 | ||
| Total stomach | 2 | 2 (100) | 0 | ||
| Tumor size(cm) | 0.127 | 0.722 | |||
| ≤5 | 58 | 38 (65.5) | 20 | ||
| >5 | 72 | 45 (62.5) | 27 | ||
| Gross types | |||||
| EGC | |||||
| I | 1 | 0 (0) | 1 | ||
| III | 2 | 2 (100) | 0 | ||
| AGC | 0.055 | ||||
| Bor.I+ II | 4 | 4 (100) | 0 | ||
| Bor.III+IV | 123 | 77 (62.6) | 46 | ||
| WHO’s histological types | 0.155 | ||||
| Papillary adenocarcinoma | 5 | 5 (100) | 0 | ||
| Tubular adenocarcinoma | |||||
| Well differentiated | 1 | 1() | 0 | ||
| Moderately differentiated | 34 | 22 (64.7) | 12 | ||
| Poorly differentiated adenocarcinoma | 63 | 38 (60.3) | 25 | ||
| Undifferentiated carcinoma | 1 | 1 (100) | 0 | ||
| Signet ring cell carcinoma | 13 | 10 (76.9) | 3 | ||
| Mucinous adenocarcinoma | 13 | 6 (46.2) | 7 | ||
| Histological grade | 0.041* | ||||
| G1+ G2 | 36 | 28 (77.8) | 8 | ||
| G3 | 94 | 55 (58.5) | 39 | ||
| Lauren’s types | 1.757 | 0.415 | |||
| Intestinal | 25 | 18 (72.0) | 7 | ||
| Diffuse | 76 | 45 (59.2) | 31 | ||
| Mixed | 29 | 20 (69) | 9 | ||
| Depth of invasion(T) | 0.662 | ||||
| T1+ T2 | 7 | 5 (71.4) | 2 | ||
| T3+ T4 | 123 | 78 (63.4) | 45 | ||
| Lymph node metastasis (N) | 7.754 | 0.021* | |||
| N0 | 31 | 16 (51.6) | 15 | ||
| N1 | 23 | 11 (47.8) | 12 | ||
| N2-3 | 76 | 56 (73.7) | 20 | ||
| Distant metastasis (M) | 0.614 | ||||
| M0 | 127 | 82 (64.6) | 45 | ||
| M1 | 3 | 1 (33.3) | 2 | ||
| TNM staging | 7.486 | 0.006* | |||
| I+ II | 44 | 21 (47.7) | 23 | ||
| III+IV | 86 | 62 (72.1) | 24 | ||
Note: *P < 0.05.
Abbreviation: TNM, tumor–node–metastasis.
EGC, early gastric carcinoma.
AGC, advanced gastric carcinoma.
Figure 2.Silencing hsa_circ_0005230 not only diminished the capacities of clone formation and proliferation of GC cells but also arrested the cell cycle.
Figure 3.Silencing hsa_circ_0005230 inhibited the invasion and migration of GC cells.
Figure 4.Hsa_circ_0005230 as a sponge to bind miR-1299.
Figure 5.RHOT1 was the downstream target gene of the hsa_circ_0005230/miR-1299 axis.